Mind Medicine (MindMed) Inc
F:MMQ
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.55
10.78
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MMQ stock under the Base Case scenario is 3.619 EUR. Compared to the current market price of 7.055 EUR, Mind Medicine (MindMed) Inc is Overvalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mind Medicine (MindMed) Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MMQ cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mind Medicine (MindMed) Inc
Balance Sheet Decomposition
Mind Medicine (MindMed) Inc
Current Assets | 299.4m |
Cash & Short-Term Investments | 295.3m |
Other Current Assets | 4.1m |
Non-Current Assets | 20.4m |
Intangibles | 19.9m |
Other Non-Current Assets | 493k |
Current Liabilities | 33.3m |
Accounts Payable | 2.1m |
Accrued Liabilities | 8.8m |
Other Current Liabilities | 22.3m |
Non-Current Liabilities | 24.3m |
Long-Term Debt | 24.3m |
Earnings Waterfall
Mind Medicine (MindMed) Inc
Revenue
|
0
USD
|
Operating Expenses
|
-93.7m
USD
|
Operating Income
|
-93.7m
USD
|
Other Expenses
|
-4.1m
USD
|
Net Income
|
-97.8m
USD
|
Free Cash Flow Analysis
Mind Medicine (MindMed) Inc
USD | |
Free Cash Flow | USD |
MMQ Profitability Score
Profitability Due Diligence
Mind Medicine (MindMed) Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Mind Medicine (MindMed) Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
MMQ Solvency Score
Solvency Due Diligence
Mind Medicine (MindMed) Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Mind Medicine (MindMed) Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MMQ Price Targets Summary
Mind Medicine (MindMed) Inc
According to Wall Street analysts, the average 1-year price target for MMQ is 23.696 EUR with a low forecast of 12.514 EUR and a high forecast of 51.11 EUR.
Dividends
Current shareholder yield for MMQ is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MMQ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Contact
IPO
Employees
Officers
The intrinsic value of one MMQ stock under the Base Case scenario is 3.619 EUR.
Compared to the current market price of 7.055 EUR, Mind Medicine (MindMed) Inc is Overvalued by 49%.